Several commercial enzyme-linked immunosorbent assays (ELISAs) for detection of antibody to human immunodeficiency virus (HIV) infection have been evaluated, mainly in the United States and Europe, with various reported sensitivities and specificities (1, 2, 5, 6, 8, 11, (12) (13) (14) . Only a few studies, evaluating a limited number of ELISAs, using Central African sera have been conducted (15, 16) . In addition, the evaluation methods often differ: various "gold standards," such as Western blot (immunoblot) and radioimmunoprecipitation assay, as well as different Western blot interpretation criteria, have been used. ELISAs have frequently been evaluated with selected serum panels which differ from the sera that actually will be tested in the ELISA. To determine which commercial ELISAs have the highest performance level in screening diverse groups of individuals at various degrees of risk for HIV infection in Kinshasa, Zaire, we compared five assays, using two whole-virus lysate assays or "first-generation" ELISAs (Genetic Systems [Seattle, Wash.] serum samples were confirmed positive, 321 were negative, and 390 were indeterminate. The distributions of the Western blot results were calculated by population group for sera which were positive with at least one ELISA (Table 1 ) and for sera negative by all assays ( Table 2 ). Of the sera negative or indeterminate by HIV-1 Western blot, 320 had been repeatedly reactive by an HIV-1 and HIV-2 ELISA and were therefore tested by HIV-2 Western blot (Fig. 1B) . None of these samples were confirmed positive for HIV-2; 225 serum samples showed no bands and 95 had indeterminate HIV-2 Western blot results. The sensitivities and specificities as well as the predictive values of the five ELISAs were calculated by population group (Table 3 ). The band patterns observed among the samples with indeterminate Western blots are described in Fig. 2 4 presented with weak minimal-positive Western blot patterns: 2 had p24, p64, and gpl20-160 bands, 1 had p24, p53, p64, and gpl20-160 bands, and 1 had p24, p55, and gp120-160 bands. These four sera were positive only by the two DuPont ELISAs and were antigen. Furthermore, the follow-up results failed to confirm seropositivity by the same USPHS criteria. Therefore, if sensitivities are recalculated for group 3 after correcting for the four weakly positive specimens according to the USPHS criteria, then the Vironostika, Genetic Systems, and Abbott assays each have a sensitivity of 100%. Thus, the current USPHS criteria for Western blot interpretation may not be applicable to African sera, given the high frequency of indeterminate bands seen in this population.
The specificities of the various ELISAs used showed significant differences, varying from 51.7 to 98.4% in the three combined groups, with the lowest values in the population group at lowest risk for HIV infection. Screening assays which lack specificity entail significant costs because of the need for additional confirmation assays.
The negative predictive values obtained for the five commercial ELISAs had a rather narrow range (97.1 to 100%), in contrast to the positive predictive values, which had an extremely wide range (6.6 to 100%). Surprisingly, one of the two first-generation assays had the highest positive predictive values.
Although we did not specifically assess for dual HIV-1 and HIV-2 reactivity, no sera were positive for HIV-2 alone; this suggests a low HIV-2 prevalence in Kinshasa at the time the sera were collected.
The lack of a perfect gold standard for HIV testing continues to complicate assay evaluations. We found 390 serum samples with indeterminate HIV-1 Western blot patterns, or 25% of our defined "true negatives." The proportion of indeterminate samples among the total negatives (i.e., samples negative by all five ELISAs and/or negative or indeterminate by Western blot) was evenly distributed in the three population groups: 26.3, 24.1, and 24.8% in groups 1, 2, and 3, respectively. In our study design, we decided to define these sera as negative. This definition was confirmed for all of the available follow-up sera of group 3. Among the 202 follow-up samples, no seroconversions were detected in samples obtained at least 12 months after the initial analysis. Even among the 67 follow-up serum specimens from the prostitute group with a known high HIV-1 infection incidence, only four (6%) seroconversions were observed after the initial indeterminate Western blot result. Among the prostitutes with an initial negative result (Western blot negative or negative by all five ELISAs), 17 (5.1%) seroconversions were documented during the same follow-up period. Other studies have shown that most individuals with indeterminate Western blots do not appear to be infected with HIV-1 (4, 7, 9, 10) . This high prevalence of Western blot-reactive bands in uninfected individuals should raise the level of caution with which this assay is interpreted. Of 390 serum samples presenting with an indeterminate Western blot, 39.7% reacted against p24 (with or without other bands) and 9% reacted against gpl20-160. The probability that an independent combination of these two bands reflects a nonspecific reaction rather than infection is 0.40 x 0.09 = 0.036, or 3.6%. When the USPHS criteria for Western blot interpretation are used in populations with a high prevalence of indeterminate Western blot patterns, some sera with minimal positive Western blot band patterns might reflect false-positive reactions rather than infection. Therefore, the criteria of the USPHS, the World Health Organization, DuPont, and others for Western blot interpretation need to be thoroughly evaluated for Central African sera, and other alternative confirmation assays should be studied.
We conclude that, in the Kinshasa populations we studied, the negative predictive values of the evaluated ELISAs did not differ much, particularly in contrast to the widely varying positive predictive values; therefore, the most practical and cost-efficient assays which generate the fewest false-positive and indeterminate results should be selected for routine screening of HIV-1 infection. 
